The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Mike Matson - Needham & Company - Analyst
: Yes, thanks. So I guess first, can see the strong growth out of the medtech business there. With Auryon, do you have a feel for where the share is
really coming from? I guess maybe not company specifically, but like laser versus mechanical? I mean, are you mainly taking share in the laser
segment or is it really across both segments?
Question: Mike Matson - Needham & Company - Analyst
: Okay. And then just the thrombectomy space, so with AlphaVac, it's kind of a larger size device, larger I guess diameter or French size, and it's more
kind of -- it's manually operated, I guess. And it seems to compare more Inari's product and like a Penumbra, but can you maybe just talk about
the distinctions there in terms of the different options that are available in that category? And then -- well, I have a follow-up on using the Auryon
product in thrombectomy, but I'll keep that separate for now.
Question: Mike Matson - Needham & Company - Analyst
: Okay. And then with the Auryon product, assuming that that -- you are able to get that labeled for thrombectomy, how does that compare to
AlphaVac? Is it kind of for smaller clots or something?
Question: Mike Matson - Needham & Company - Analyst
: Okay. And then NanoKnife. So if I am understanding it correctly for prostate, the idea is that you are really going after patients that might otherwise
have done watchful waiting and getting them kind of earlier on. Is that right?
Question: Mike Matson - Needham & Company - Analyst
: And do you break out the growth of that product line specifically or is it just part of the medtech category overall? I'm just curious how that is
growing as opposed to the other, like Auryon and --?
Question: Mike Matson - Needham & Company - Analyst
: All right. Well, I don't really have any other questions. I don't see any questions that were submitted by the audience. So I think we are going to
have to wrap up here. But thanks for your time and it looks like you have some really interesting products that are gaining some traction.
| 
